CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
CURIS, INC. (CRIS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.70 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2021-03-16
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-12-31 was $1.50M, a 87.50% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-09-30 was $1.40M, a 100.00% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-03-31 was $1.80M, a 20.00% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $2.70M, a 35.00% increase from fiscal 2019.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $2.00M, a 57.45% decline from fiscal 2018.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $4.70M, a 30.56% increase from fiscal 2017.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $3.60M, a 0.00% change from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $2.70M 10-K · filed 2021-03-16 | |||||||
| 2019-12-31 | $2.00M 10-K · filed 2021-03-16 | |||||||
| 2018-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $2.90M derived: sum of 2 quarters · filed 2020-03-19 | $2.90M derived: sum of 3 quarters · filed 2020-03-19 | $4.70M 10-K · filed 2020-03-19 | ||||
| 2018-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.40M derived: sum of 2 quarters · filed 2018-11-01 | $3.20M 10-Q · filed 2018-11-01 | $4.00M derived: sum of 4 quarters · filed 2019-03-26 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $1.80M 10-Q · filed 2018-08-02 | $2.60M derived: sum of 3 quarters · filed 2019-03-26 | $3.30M derived: sum of 4 quarters · filed 2019-03-26 | ||||
| 2018-03-31 | $1.80M 10-Q · filed 2018-05-03 | $2.60M derived: sum of 2 quarters · filed 2019-03-26 | $3.30M derived: sum of 3 quarters · filed 2019-03-26 | $3.90M derived: sum of 4 quarters · filed 2019-03-26 | ||||
| 2017-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $1.50M derived: sum of 2 quarters · filed 2019-03-26 | $2.10M derived: sum of 3 quarters · filed 2019-03-26 | $3.60M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.30M derived: sum of 2 quarters · filed 2018-11-01 | $2.80M 10-Q · filed 2018-11-01 | $3.60M derived: sum of 4 quarters · filed 2018-11-01 | ||||
| 2017-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $2.10M 10-Q · filed 2018-08-02 | $2.90M derived: sum of 3 quarters · filed 2018-08-02 | $3.50M derived: sum of 4 quarters · filed 2018-08-02 | ||||
| 2017-03-31 | $1.50M 10-Q · filed 2018-05-03 | $2.30M derived: sum of 2 quarters · filed 2018-05-03 | $2.90M derived: sum of 3 quarters · filed 2018-05-03 | $3.60M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2016-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.40M derived: sum of 2 quarters · filed 2018-03-08 | $2.10M derived: sum of 3 quarters · filed 2018-03-08 | $3.60M 10-K · filed 2018-03-08 | ||||
| 2016-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.30M derived: sum of 2 quarters · filed 2017-11-07 | $2.80M 10-Q · filed 2017-11-07 | $3.40M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $2.20M 10-Q · filed 2017-08-03 | $2.19M 10-Q · filed 2016-08-04 | $2.80M derived: sum of 3 quarters · filed 2018-03-08 | $3.37M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2016-03-31 | $1.50M 10-Q · filed 2017-05-04 | $1.50M 10-Q · filed 2016-05-09 | $2.10M derived: sum of 2 quarters · filed 2018-03-08 | $2.67M derived: sum of 3 quarters · filed 2018-03-08 | $3.30M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2015-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.17M derived: sum of 2 quarters · filed 2018-03-08 | $1.80M derived: sum of 3 quarters · filed 2018-03-08 | $2.70M 10-K · filed 2018-03-08 | $2.73M 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $571.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.20M derived: sum of 2 quarters · filed 2016-11-03 | $2.10M 10-Q · filed 2016-11-03 | $2.12M 10-Q · filed 2015-11-09 | $2.79M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2015-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.53M 10-Q · filed 2016-08-04 | $2.22M derived: sum of 3 quarters · filed 2017-03-09 | $3.05M derived: sum of 4 quarters · filed 2017-03-09 | ||||
| 2015-03-31 | $896.00K 10-Q · filed 2016-05-09 | $1.58M derived: sum of 2 quarters · filed 2017-03-09 | $2.42M derived: sum of 3 quarters · filed 2017-03-09 | $2.89M derived: sum of 4 quarters · filed 2017-03-09 | ||||
| 2014-12-31 | $687.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $1.52M derived: sum of 2 quarters · filed 2017-03-09 | $1.99M derived: sum of 3 quarters · filed 2017-03-09 | $2.90M 10-K · filed 2017-03-09 | $2.91M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $837.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.30M derived: sum of 2 quarters · filed 2015-11-09 | $2.21M 10-Q · filed 2015-11-09 | $2.62M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $466.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.38M 10-Q · filed 2015-08-06 | $1.78M derived: sum of 3 quarters · filed 2016-02-29 | $2.28M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $910.00K 10-Q · filed 2015-05-07 | $0.00 10-Q · filed 2014-05-09 | $1.32M derived: sum of 2 quarters · filed 2016-02-29 | $1.82M derived: sum of 3 quarters · filed 2016-02-29 | $2.34M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $908.00K derived: sum of 2 quarters · filed 2016-02-29 | $1.43M derived: sum of 3 quarters · filed 2016-02-29 | $2.72M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $1.02M derived: sum of 2 quarters · filed 2014-11-10 | $2.31M 10-Q · filed 2014-11-10 | $3.07M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $522.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.81M 10-Q · filed 2014-08-07 | $2.57M derived: sum of 3 quarters · filed 2015-02-24 | $3.10M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $1.29M 10-Q · filed 2014-05-09 | $2.05M derived: sum of 2 quarters · filed 2015-02-24 | $2.58M derived: sum of 3 quarters · filed 2015-02-24 | |||||
| 2012-12-31 | $764.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $1.30M derived: sum of 2 quarters · filed 2015-02-24 | $2.52M 10-K · filed 2015-02-24 | |||||
| 2012-09-30 | $533.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $1.76M 10-Q · filed 2013-11-12 | ||||||
| 2012-06-30 | $1.23M 10-Q · filed 2013-08-08 | |||||||
| 2011-12-31 | $1.50M 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |